Drugs / GSK4418959
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06710847 | Dec 2024 → Jun 2026 overdue | endometrial cancer, rectal cancer | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4418959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06710847 ↗ |
| Action | Inhibit | “DNA Helicase Werner Inhibitor” NCT06710847 ↗ |